id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0371-0007,FDA,FDA-2011-E-0371,FDA/CDER to U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-12-28T05:00:00Z,2012,12,2012-12-28T05:00:00Z,,2012-12-28T13:21:29Z,,0,0,090000648119d57c
FDA-2011-E-0371-0006,FDA,FDA-2011-E-0371,FDA\CDER to U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-04-09T04:00:00Z,2012,4,2012-04-09T04:00:00Z,,2012-04-09T12:40:08Z,,0,0,0900006480feb75b
FDA-2011-E-0371-0005,FDA,FDA-2011-E-0371,Determination of Regulatory Review Periods for Posposes pf Patent Extension: NATROBA,Notice,General Notice,2012-04-06T04:00:00Z,2012,4,2012-04-06T04:00:00Z,2012-05-06T03:59:59Z,2012-04-06T13:43:20Z,2012-08337,0,0,0900006480feab23
FDA-2011-E-0371-0004,FDA,FDA-2011-E-0371,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-03-12T04:00:00Z,2012,3,2012-03-12T04:00:00Z,,2012-03-13T12:01:00Z,,0,0,0900006480fd3b2d